---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062955"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:59:15.459062+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Oncology SPAC merger S-4 effective; shareholder vote set for Aug 4, 2025

## Summary
- SEC declared Registration Statement on Form S-4 effective for Helix/BBOT business combination.
- Extraordinary General Meeting of Helix shareholders scheduled for August 4, 2025.
- Record date for shareholders entitled to vote is June 30, 2025.
- Business combination expected to close in August 2025, subject to conditions.
- Post-close company will be renamed BridgeBio Oncology Therapeutics.

## SEC filing metadata
- accession: 0001213900-25-062955
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025062955/0001213900-25-062955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025062955/ea0248655-8k425_helix2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062955
- JSON: https://secwatch.observer/filing/0001213900-25-062955.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.